first they get genetic day tark -- data and start partnering with pharma companies to do startup andhey want to turn those that into drugs. caroline: they just got approval and now they're like, let's make drugs. this is moving rapidly. cory: ann's comments to you were hilarious. caroline: she was joking, she was like, we got that test approved, what's next? cory: start a drug company, why not? what advantages does 23andme have when it comes to drugs? caroline: a lot of discoveries are based on a single discovery by a scientist, but 23andme has data from 650 test that they've -- 650,000 customers who consented to let them use data for research. they can look at the data and say, are there genetic components leading to these diseases that patients have, and use that to start finding drugs. cory: they might be able to discover new things that no one has known before first because they have the data. caroline: and not only do they have your genetic information, whenever you log back in to 23 and me, they have a question box. they'll say what did you have for breakfast? do you smoke? wha

then take pharma or more precisely, the two pharmas. you have traditional pharma companies like merck and ely lilly. when the dollar depose higher these companies get sold sold, sold. but then there's regeneron, up another 16 points today off its new cholesterol drug. ors or esperrion. positive clinical trial data on that cholesterol pill sent the stock soaring 29% today. an astonishing move. esperion tweeted it was going to come on, but canceled at the last minute because it filed an equity offering to take advantage of the stock's strength. then there's activist a giant drug company that closed on its acquisition of cramer fave allergan earlier today. the key thing you know about activist, it's a growth plan that's not known by the same rules that pfizer or lily play for, which is why it rallied up $2.50 why the old line pharmas didn't do so hot. now, again, before this year before this year started, we didn't see this kind of disparity within various groups. it was very rare to see a biotech diverge from the older drug companies, it

other big pharma goes out and finds patients to use as lab rats but they say they have a relationshipith patients, to say, you can help with this. they think that will make them different. cory: is that an advantage they have? is that an extensive part of testing and -- expensive part of testing and designing drugs? jay: you spend a lot of time waiting for food and drug administration getting back to you when you request to start a trial or if they need to review data and they could ask for more data. even just the final step of submitting your new drug application to f.d.a., they have nine months to review it and get back to you. and i don't know if this is going to speed that up. cory: thank you, jay and caroline. "bloomberg west" will be right back. ♪ cory: you're watching "bloomberg quest" -- "bloomberg west" where we focus on technology. russia has expanded its presence in latin america in ways that signal, quote a clear return to cold war tactics, end quote. that's according to the general commanding u.s. southern forces john kelly. in a statement to the senate armed services co

if oil goes back to $80, the ftse versus pharma. pharma has been a safe sector. safe havens in pharma stocks. it is the place to be like the energy sector was. $80 oil out of pharma into energy stocks for jonathan: if this is $80 oil, what assets will stay here? $60 on brent. karen olney: the rolled -- of the world has to readjust. look at 20 or 30 years oil was always around $10 or $20. the world readjust. energy has come down. no longer a dry are european markets. jonathan: karen olney will stay with us. we put those vertical chinese stocks in context when "on the move" returned. join us in two. ♪ jonathan: welcome back. i am jonathan ferro. this is "on the move." some of the top stock stories. sales of sainsbury have missed estimates. the retailer reported a fifth straight quarter of sales declines. sales dropped to less than estimated. peoples seem to like when things are less bad. autos are up. auto sales raising several percent for the month of february. i want to look at stocks. the china equities surge continues. the shanghai prices not seen before the fi

you invest in pharma. this is an interesting development.ay: it is certainly big news, a surprise to us. cory: why is a big news? jay: you don't think of 23andme as a company that would go into drug discovery. cory: is this a direction we will see of companies that are doing rock tech stuff with electrons and big data and exploiting that? or is this really a specialty that it will be able to exploit? jay: there are lots of ways to solve this problem. there are nonprofit entities that have big genetic data they can use. a lot of great discoveries in terms of the mechanism that comes out of academic and nonacademic institutions. cory: there's this a fairly unique approach, to start with massive piles of data and try to find a drug within it? caroline: yeah, it is unique. those that have taken the approach of working with pharma companies already have been selling chunks of genetic data to pfizer and companies to partner. now they are doing it on their own. cory: do you think selling data to pfizer will hurt the cousin now it will be a competit

we have the pharma stocks you need to buy right now to cash in on the latest advancement. against heart disease, but first, let's head over to nicole at the new york stock exchange with the pull of the floor. >> with pulse of the tkphraorb floor, jason weisberg, sea port security. what do you make of it? >> i think year end we're going to be at highs, however. as we discussed last week, market will react, opposite direct of commoditys and the dollar. we see a strongeer dollar the market will sell-off,' op set the market reacts like today. >> i wanted ted to talk about or energy plays, oil near a 6-year low? >> i think oil is in a stable spot between 45 and 50, if you look at charts of oil, in particular, this suggestions we're locked in as long as we're locked in with some form of sta billy the markets will bounce off. >> do you think that feds should raise rate? >> i will trust whenever they want to do, i am not an economists. >> all right, thank you very much, back to you tom. >> thank you. here to help, our investment pros, dani hughes, and scotti neil hughes. hitha her

we mentioned jim mentioned and other guys mentioned about pharma. a lot of guys looking for these assets. biotech stays strong. buy it intelligently and don't chase it. that's it. >> we're just getting started. coming up the latest on the situation in the middle east that has oil on the move today and our call of the day is a downgrade of sandisk. the stock is plunging today on its own warning. walter made the call on the downgrade today and here to defend it and much more straight ahead. opinions. there's no shortage in this world. who do you trust? whose analysis is accurate? how do you make sense of it all? a simple, unbiased stock score consolidated from the opinions of independent analysts... is that too much to ask? nope. equity summary score, powered by starmine, will help you execute your ideas with speed and conviction. and it's only on fidelity.com. open an account and find more of the expertise you need to be a better investor. you can call mbut,allow... i have a wandering eye. i mean, come on. national gives me the control to choose any

new at 6:00, kpix 5's len ramirez is live in sunnyvale on the pharma cyclist. >> reporter: there have been a lot of big deals in silicon valley over the years and this is another blockbuster but unlike some of the previous deals that involved high-tech companies that everyone already knows about, these are companies involved that most people have never heard of that is until now. the sunnyvale headquarters of farm pharma cyclics, the company's successful cancer drug [ non-english language ] and that's the $21 billion difference. >> it has global implications. this is one of the most important transactions in the state this year. >> reporter: technology analyst is talking about a deal that may put silicon valley on the map for pharmaceuticals. >> typically you see this kind of thing happening on the east coast where there's more pharmaceutical activity but as we moved up to high-tech pharma, that activity seems to be moving over here. >> reporter: chicago based abbvie outbid several other companies including johnson & johnson to take over pharmacyclics and its most promising product. t

>> big pharma they have to buy and see whether the huge prices that's profitable. think that the reality is that this iseshas been go on since the beginning of time weep tend to go through cycles where there's tremendous productivity in r and d and other periods they drill dry holes if you will. people looked at gilead's purchase at $11 billion several years ago, as being crazy, and now of course you know they'll probably have $11 billion in sales from one single drug. so you know beauty is in the eyes of the beholder. >> what do we buy? what should people look at now in. >> you've got companies like actavis the mark is high on prospects. >> that's not innovation, is it? it's due to the role of strategy they seem to be pursuing? and the fact they're inverted as well, which done hurt. >> you bring up a great point. don't forget they're going to spend close to $2 billion in r&d, allergan's a company driven by innovation by botox but your points well taken. the market is going to be -- is going to continue in this environment to be willing to pay a lot, a big premium

liz: i believe pharma, horizon pharma, are two names you feel are -- >> one of them have been -- we've been talking about pharma sigh clicks. it has been taken out for $250. so the point, yes he made a good call. more importantly shows you what is really going on underneath the coverage. you don't have drugs improving life. they are extending life, curing diseases. this is happened in lukemia and help c. things on -- hep-c. this is on the melanoma front. i hate to say it all the time but i will only say here, we have a sea change with what is happening with the life sciences companies. when you win here, you're not doubling or tripling money. you're making far outsized gains with more exposure. david: i am glad you only said it here, only for our audience. bob, i have to ask you about oil. down another 4%. you say it could go down to $35 a barrel but you like exxonmobil. why? >> well, if you remember, david, you're a daisy if you do, i said this a month ago, i said i wanted to buy s&p $50 lower. we're here down $45 lower. david: i remember you do. >> i said oil down to $35 before may.

horizon pharma, hznp? >> they are buying companies and marketing them.e built a large company. they were one of the last companies in the fall that did one of the inversions we talk about. they were one of the last companies so to have that merge with an irish-based company. they have excellent management team, leveraging recent sales force. the recent merger was one of the four yesterday in the disease areas, orphan disease areas, and running 15 times target this year. this stock could go a lot higher because of the acquisitions we talked about. liz: we've got 20 seconds, alnylum pharma, that is a lesser known name. >> undiscovered world of rnai. they are in orphaned diseases that have huge markets, some of the markets could be extraordinary. i expect the market to go higher. liz: shoutout to j and p security, you are one of the underwriters for the deal tonight, godaddy. congratulations, we have the ceo tomorrow, blake irving, he's live in studio. good luck on that one. mark lehmann. closing bell, let's put the names up, the biotech names on the facebo

intersept pharma inside pharma. get to some of the highlights of the pick is there any biotech bubble out there? you see it on banners and graphics. is it there or are these returns really deserved? >> it's a great question and i think there's no doubt that we're in the midst of a biotech boom. the question is whether we're in the midst of a biotech bubble. it's tough to answer. there are a lot of things going right in the sector which the bulls can use to justify a valuation. first you have scientific progress. really at an all-time high going back you know 20 years. the fda, which is the main regulatory body in the united states, is working with companies to get drugs approved faster rather than city setting up roadblocks and delaying the arrival of new drugs. it's just been a confluence of these sort of factors which has really cautioned this sector to explode over the last two, two and a half years. >> one of your techs a little too small to talk about. i want to focus on two that are big enough to get into here

you take some of the large cap pharmas and you add them to one of these midcap biotech names.'ve got that octane in the biotech, but have you the stability in the large cap pharma. >> anybody want to talk about gilead? >> take a look at the chart. look at how it's held on to the 50 day underneath $100 a share. it's been going like that for quite some time. this is a company that every once in a while gets something like this where you have that big downward shot. people get very, very excited and very interested when they suddenly see some of the things. it has held support so far. i think you have to look at that 50-day moving average. >> through hours left. quick break. plan for the second half coming up. at mfs, we believe in the power of active management. our teams collaborate around the world, which leads to better decisions for our clients. put our global active management expertise to work for you. mfs. there is no expertise without collaboration. ♪ ♪ (under loud music) this is t♪ ♪lace. their beard salve is made from ♪ ♪ sustainable tea tree oil and kale... you, my fr

has put on that, you can put on tomorrow. >> "fast money," weekdays 5:00 eastern on cnbc. >>> big pharmacing big bets on brand-new technology. glaxosmithkline developing a brand-new way to possibly conquer diseases from cancer to arthritis. using electric signal inside your body. joining us is meg turrell and glaxosmithkline chairman of global vaccines. meg, start with you. can you explain what this is? >> i will try and they'll correct me if i get it wrong. it's a fascinating new idea. we know about pills, injectable medicines. glaxo has been trying to think of a new way to deliver new medicine and treat disease. what they want to do is tap into electrical signals that govern all of the organ functions in our bodies. by doing that with really tiny devices, they'll be able to clip those on to nerves and control the things that are going wrong, the signals going to our organs causing disease or other things. they even talked about infertility as something they could potentially address with this. super fascinating. probably a few years off from market. >> can you give us an example of how

the pharma sector drove last year and doesn't appear to be slowing down in 2015.st on a deal between two drug makers coming up after this short break. >> it was a blockbuster year for deals in the drug sector in 2014 and companies still have plenty of ammo to continue making acquisitions this year. let's get out to landon that has all the details as ever. >> wilfred that's exactly right. the drug and health care industry has been fuelling the surge over the past year as companies seek to refill their pipelines with new treatments to replace treatments losing sales or coming off patent. the latest deal, abbvie buying phamacyclics. they'll pay $261 a share. it's a 13% premium to wednesday's closing price. they expect it to start adding attorneyings and revenue by 2017. it gives them access to the promising blood cancer drug. it's already been improved to treat four rare forms of the disease. they are projecting it will generate $1 billion in shares this year. they've seen a huge turn around as far as back in 2008. it dipped by more than $1. it took many by surprise

boding pharma and finance. bingo! ♪ alleluia ♪ >> i've got to go to my home state.n new jersey. bob? >> caller: hi, cramer, how are you doing? >> not bad. how are you, bob? >> caller: oh, i'm kind of snowed in here. i can't believe it. a big boo-yah to you. you are the best! >> thank you. thank you very much. >> caller: thank you. listen i have a few stocks and want to know if i'm diversified or not. >> let's go. >> caller: okay exxonmobil chevron, general electric cisco systems and mcdonald's. >> i think bob is from southern jersey. someone the other day was saying i can't stand cramer's philadelphia accent. i do not have one. or when you have one, you can't tell you have one. so, you can say i have one, but i don't know it okay? all right, oil, uh-oh, two oils. we'll get rid of that one. bristol-myers. a diversified conglomerate a restaurant and a really really good technology stock. put bristol-myers in there, get rid of exxon and i'm a happy camper! stick with cramer. why are we so committed to keeping you connected? why combine performance with a conscience? wh

. >> when purdue pharma launched oxycontin, they launched a marketing campaign and an educational campaign to convince the medical community that we had been under-prescribing opioids. >> there's no question that our best strongest medicines are the opioids. >> to convince us that we had been allowing patients to suffer needlessly because of what they called an overblown fear of addiction. >> the culture actually of the time was lets treat everyone with opioids at whatever dose necessary and if some doesn't work we'll give a higher dose. many of the patients i would have to keep increasing the dose that brought them up to doses that i didn't feel were safe. i consider it a population-wide experiment on american citizens that let's just give them all opiates. >> here in seattle doctor david tauben is part of a group of physicians who are changing their approach to treating pain. >> okay, so when i just slightly press does that hurt? >> it's a response to a staggering reality: in 2010, doctors prescribed enough opioid painkillers to medicate every american adult around the clock for an entir

we talked about zio pharma not that long ago. move that has made in the last week and a half or so. look at the volumes in some names as they get close to getting drugs to the market or potentially in front of the fda. you can see some of the dramatic moves you can get as well. >> joe? >> a premium being paid for growth and growth is found in the health care industry and not surprisingly enough and i don't know if the news sticks or doesn't stick but there was always the expression that we had in the trading community bad news follows bad stocks. good news always good performing stocks. see that today. you should have been in the health care space at an overweight to gyp with before today. now you get good news not surprising. >> trader blitz, three trades on three stocks making news today. first up smith & wesson is popping after beating expectations they raised the their goodance as well, pete. >> that was the big thing. we talked about this yesterday, just yesterday, under the radar about the ammo and some of the moves that we

pharmaing is their way to tackle the illegal trade. the project is small but the ambition is big. nicholas heart, al jazeera. festival, it is the largest gathering of aspiring film makers and emerging ini have tars. we are bringing you some of the best. neuroscientists are treating disease in ways they have seen nothing short of science fiction, and i catch up with one of the world's leaders

pharmaing is their way to tackle the illegal trade. the project is small but the ambition is big. nicholas heart, al jazeera. festival, it is the largest gathering of aspiring film makers and emerging ini have tars. we are bringing you some of the best. neuroscientists are treating disease in ways they have seen nothing short of science fiction, and i catch up with one of the world's leaders that is making limbs that in every guy, emulate a biological body. and could advancements in virtual and haul graphic technology bring back the dearly departed in we will find out. for the 29th year, of this very protegee yous event, for fill and music, and we have raj back in the studio in d.c., he is bringing in all of your feedback and questions for the program. >> that's right. throughout the show, we want to hear from you. all of the questions and comments you have tweeted in. some fascinating desks to dive deeper. all here to network, and learn about the latest in science, technology, food, film and music. and you can imagine the palpable energy so many creative nontraditional thinkers a

he's put together a growth pharma we don't have those.feel it's done with smoke and mirrors because of the inversion. allergan was a great company. if he can monetize allergan -- the stock's going higher. >> allergan expands the pipeline in different ways. >> botox is a pipeline within a pop pipeline. many off-line uses that can be commercialized. it's the great miracle drug of the era when it comes to muscle relaxation. works for migraines, different muscles people need relaxed. studies galore and actavis will take advantage. people feel david pyott didn't do enough with botox. i thought he did tons. >> or perhaps marketed in a way long term created perceptions that maybe fought against -- >> that's it. that's it. what happened with botox, that it got a bad name, so to speak, being for brazilian supermodels. he used botox, even those he's 44 to show how great it is. try makeup that can also do it. >> and mgm. >> we have land and buildings, great name for activist, aut to convert to reit for some of the stock, real estate value, 70% upsid

our road map a trio of multi-billion-dollar pharma deals. we're going to break them all down for you. >> tim cook penning an op-ed against indiana's religious freedom law. while the ceo of angie's list explains his halting of expansion in the state. >> ford reviving the iconic lincoln continental, and we will start to ceo mark fields live in just a few moments. stock futures up after a chinese central stock bank owner said he saw more room. about $12.8 billion in cash. and then of course the personal income rose .4% but spending was up a weaker than expected .1. you were talking about these deals with joe back at hq. a bunch of deals this morning. >> i think what's worth watching is how much the acquirer is going to go up. you have a deal like horizon had them on "mad money" because of their tax status. it's a terrific deal. an orphan drug. they tend not to go into orphan drugs, but that's what they're doing. you'll see united health go up because there's a scarcity of pharmacy benefit managers. these are percolating. but it is -- the future

mark: the drugmaker valued at $21 billion, we take a look at mega mma in the pharma industry. welcome to countdown. anna: coming up this morning another bloomberg exclusive, we will go live to paris and speak to the ceo of j.crew as they open their first boutique in the country. mark: and cather -- qatar airways chief executive talks about his rival delta. let's get to one of our top stories, china's national people's congress continues today. as was widely expected the premier set out an economic growth plan of 7%. rosalynn joins us from beijing with more. what do you know about this figure? rosalynn: it indicates they're trying to project a slowdown and are encouraging innovation which includes the quality of growth. here in china. he has said in the past that he will tolerate a lower level of growth as long as enough jobs were created. if you look at last year, the growth hits 7.4% and there were 13 million jobs created interurban areas -- in urban areas. way more than the target. a 7% figure is manageable because there will still be growth in the job market. this number do

some m&a in the pharma space. treasuries are gaining on disappointing factory data. the fomc meeting -- or announcement -- is on wednesday. all right, wti at a fresh six-year low. storage is nearing capacity. that means more pressure on prices. quantitative easing, the weak euro, and central-bank divergence. the dax is at a record high with the final hour of european trading getting underway. the ftse the oil companies are the biggest decline or there. the cac 40 is climbing to a seven-year high, as well. swiss stocks are rallying today. i can't pull up the one-day chart, but the three-day chart -- that is not cooperating either. what you will see on the six-month chart is the benchmark stock index has recovered from almost two months ago. you can see that in the recovery. a lot of people said the stronger u.s. dollar benefits swiss companies. alex: thanks. stephanie: way, way way back in 2012, the super pac was new and no one was quite sure what to make of them. president obama and mitt romney were super cautious

big pharma's not going to do it it's going to be you and guys like you. >> you're correct. research in the biotechnology area which are coming to fruition today. i think that's what investors are realizing. and for our company specifically, our dew -- >> you guys might want to talk, i think. >> i agree with the construct and as i mentioned to you i think the medical research going on right now is really phenomenal enabled by a set of tools in terms of genetic sequencing and the use of big data that didn't exist. that is allowing the development of breakthrough drugs in so many different areas. and i was only semi-joking when i said if you look for the next ten years, you'll make it beyond that. i really do see the pace of drug creation to deal with many of the diseases that over the last 30 or 40 years we found very difficult to deal with is huge opportunities. >> cancer diabetes. >> yeah. the breakthroughs we're finding to stimulate the immune system to deal with cancers and other sorts of disease is really pretty amazing. the ability to do very high speed gene sequencing

day macau would not say what i a member from a strategic perspective feisty the bio pharma small-capid cap biotechnology stocks because there is people in the stocks that look for any excuse to sell. as a good down with the interest-rate rise and i along and those that have balance sheets that have growth and research and development semitist -- just taken a broader look with the big breakout. >> i could definitely riding from the blue chip stocks but the stocks like apple are continuing to go about the end of the year but for volatility perspective i'm not trying to pick the bottom or the top. charles: that is one of the themes of the show but if you are a hedge fund any other space or sector? >> i think consumer discretionary that we have to be ready when oil prices do go up with these consumer discretionary type of stocks >> thanks a lot. congratulations. when it is unemployment the fed has appeared pretty confused. told a. tweet me. we will break it down next. ♪ in my world, wall isn't a street. return on investment isn't the only return i'm looking forward to. for some, every do

that is the biggest pharma deal of this year. they managed to come in in the last minute and barge johnson & johnson out of the way and snap up the company, but why? it is all about the drugs they produce. in particular pharmacyclics makes one that is so good for cancer patients because it avoids certain serious side effects when you're having chemotherapy. this is a stellar drug and analysts say this is one of the best-selling cancer drugs of all time. no wonder they were fighting so hard. already johnson & johnson have a deal to make this drug with arma cyclic's, they didn't go -- with pharmacyclics, they didn't go with her partner. nevertheless, it boosts abbvie's pipeline. >> this is one of the first mega deals of 2015. they have been knocking on locked doors. >> shy a was the deal -- door they have been desperately eating at but that deal got canceled because the tax efficiencies didn't work anymore. they changed some of the rules and no longer being in ireland would've helped but only a mega deal. >> coming up, the ecb is o

and hyperion is being bought by ireland's pharma.>> it does. if you're looking at the companies, they're more valuable with a foreign corporation who could take the same sales and lower taxes. >> and another we're talking about in this teva acquired california-based auspex for $101 a share or $3.2 billion. >> when you start looking at deals, the foreign company is always going to be able to pay more for a deal than the u.s. company would be able to because they can pay lower taxes on it. that's why we need a fix when it comes to corporate tax rates. >> i would agree. >>> also a state law in indiana causing a national outcry from the business community that governor michael pence can't silence. mary thompson joins us with more from indianapolis. good morning. >> good morning to you becky. this law is seen as providing legal cover for businesses that want to discriminate against members of the gay and transgender communities. governor pence says it's about empowering people but certainly state and national businesses don't see it that

off the week in high gear, one day before wrapping up the first quarter of the year a flury of big pharma deals helping the dow briefly reclaim 18,000 as it joins the s&p powering back into the green for 2015. look at lumber liquidators. our very own charlie gasparino moving markets this week with a scoop on carl icahn. charlie tells the story. >> here is what we know. i can't tell you if carl will get involved in the stock or not. he is an interesting guy. he plays a lot of controversial stocks. hlf, herbalife, he is still involved in. his staff is looking whether to get involved in this we don't know whether he will go long or short. we don't know whether we will get involved. there is no decision yet on the table. i posted this on twitter, this is somebody inside of carl's office, sometimes comes down to carl makes his move who does he hate less? does he hate longs or shorts? as you know -- melissa: he loves money. i don't think he cares about people that much more than money in this situation. >> the one of the, shorts on this as you know is whitney tilson. i emailed whitney tilson. i

pharma makes no sense to me either. not discounting correctly. last week when they made a play for salecs they went on the air sitting next to me and he said that val yanlt will have to raise the bid. i said when they did, both stocks would go higher. everything came to pass in the trade worked. that's nutty. it's not supposed to -- stocks aren't supposed to be hit like this. take the absolute favorites, harmon. we've been saying they're the play on the technology. a major research firm comes out and says it's the play on the connect a car. that means we do another car company. tesla. the stock and car person tweeted this very weekend that he'll have a major software announcement set for thursday that will alleviate range anxiety which i guess is a disorder that grips tesla drivers. the tlaes will rally into the meeting and then keep rallying after the meeting as short sellers get run over and they raising in that they say. as guess the market continues on its merry way. here's the bottom line. this market can't anticipate anything positive becau

enzyme especially pharma.sn't have what i want which are the big phase 3 drugs that are about to go on the market. let's go to benjamin in indiana. benjamin? >> caller: hey, jim, thank you for all you did for the home gamers. >> quite welcome. >> caller: duke energy. >> all the utilities have been slammed over the false fears that the fed will start raising. i will see you and raise you with dominion. justin in california, justin? >> caller: hey jim, a big booyah from sunny san diego, home of the aztecs. >> true. >> caller: first time caller. thanks for all you do. i love your show. >> thank you. >> caller: i wanted to get your thought on the amino therapy nas named northwest bioer this a? >> it's a controversial stock. i have to do more work on its before i opine on that. it's one of those that's a week to week. okay? i can't give you on -- i can't cuff it. let's go to nick in new jersey. nick? >> caller: booyah jim. >> booyah nick. >> caller: i'm a big fan of your work. i want to know you talked about the so

forget biotech out of major pharma stocks. operating margin is 52% operating margin.ig deal. it's only phase 2. you get it to phase 3 you'll add another 10 bucks on the stock. celgene to me continues to go higher. don't trade apple. same thing with celgene. own it, don't trade it. >> are you in biogen? >> pete is but, again, this is phase 1, right? tomorrow with biogen. that's phase one with them about the monochromal antibody. the pe is up there in the stratos fear versus biogwen. >>> tesla coe elon musk says hands free is own a few months away. so why did the stock sell off after the big vote of confidence? a deeper dive into what's behind that move. that's next. yes, when others focus on one thing, you see what's coming next. you see opportunity. that's what a type e does. and so it begins. with e*trade's investing insights center, you can spot trends before they become trendy. e*trade. opportunity is everywhere. >>> "fast money" live from the nasdaq. tesla has anxiety and is giving some investors anxiety about the stock. we have an analyst that says you should buy

i said celgene, biogen those are the four horsemen of the big pharma apocalypse.ou cell, cell, cell. these have gone up let's say almost in a straight line. and that's the caveat i want you to focus on. almost. when they do have their downturns, and they do, they are severe and ugly and you really don't want to buy them before those downturns. it's like yesterday. i wrote on twitter at jam cramer that everyone who complained about my recommendation of isis pharmaceutical are saying they paid the top price because it did slip down after that. listen to me, you're now up on your position. it hit an all-time high today. you're free to sell. if only so you don't blame me for any losses that you might incur. i tire of being accused of getting it wrong when thankfully, i really got this right. and i'm telling you, i don't want you to be greedy. look, i know these stocks if can still go higher and many will but i also don't want to hear, you cut me out of the next 100 points in biogen. but can i just stress, don't you think the easy -- can't you agree with me? don't you

a story about ghost writing in which i was approached by a medical education company, a vendor to pharma, to put my name on an article that had written about interactions. and when i asked about the genesis of this article, i was told that a drug company astrazeneca, came up for regulatory approval in a few years and it had fewer drug interactions than warfarin. so this company was charged with posting an article in the medical literature that would talk about herb interactions and i am sure there were putting in other articles to talk about what problems it had in terms of drug interactions just as a way to prepare the market for another drug that had fewer interactions. that is not something that you would necessarily identify as promotion. the article does not mention the drug that is actually being targeted. it was a drug that ended up not being approved in the united states anyway. it is the kind of promotion that can happen many years before the drug comes on the market. brian: i found this on wikipedia, the list of the largest pharmaceutical settlements. the top one at the moment,

meg terrell, a big play here on pharma benefits.harmacy benefit managers, what they do in part is negotiate drug prices on behalf of health insurers and unh is a health insurer, and it's consolidate, but it owned its own benefits manager. what i'm hearing from people today is this is further consolidation in this industry giving these pbm's a lot more power. we're even seeing them use this power on drug prices. the biggest pharmacy benefits are now express scripps, cvs, and united health combined with catamaran. there are a couple of implications on the deal here. express scripps -- it's not just combined with a health insurer or pharmacy which cvs is combined with. will we see a potential combination there for express scripps? the second is on drug companies stocks because if these pbm's get more and more powerful as they get bigger at the top as this deal does they're going to get more drug pricing negotiation power which we've seen play out in hepatitis c. >> clearly, the scale helps. what you are saying is there are not a lot of

. >> drop for intercept pharma. >> issuing out more shares. 2.2 million shares. an insider last week selling 200,000 shars. i don't think you necessarily have to jump into this at any point in time. you've got to find names that fit whatever portfolio you are comfortable with. this is one with absolutely no earnings yet. very interesting company, but i think you want to wait right now. >> pop for priceline. >> upgraded the name. $1400 price target. if you look at the stock since january, the move down we've seen recently is a 50% correction of the move we've seen this year. i think against sort of 1,100ish. >> and pop for dangdang. >> for a beligered sector, these guys beat on the sense. but the top line was better. they grew about 23%. they are delivering. i think the market was very short this name. i don't think you need to buy it tomorrow, but look at a lot of these names. >> and a pop for coyote ugly. we're not talking about the famous chain of pubs that made the set for the film. meet the real coyote. spotted this morning on a rooftop of a bar in new york.

. >> i'm in the big pharma names and not as much as bioteches because incredible pipelines and starto what they trade. biojen, just on the hope for something in these phase threes but i tell you what. it makes me nervous when i hear you say 20% down potential if things aren't so great. that's a pretty big hit to the stock. right? >> yeah, if you look at the items, come back to this. you just quoted, ibb up 17% to year-to-da year-to-date. but if you look at ibb, biogen is number one and then gilead and a.mgen. if you're in the name, you're going to shoot urs yo if it's up 25%. >> that's what -- >> i've been playing the sis si way up a long, long time. fdt and fbl. >> after the break, big day for alibaba. the stock holding on to gains into the close, so it's bottomed out. mark maheni in the house. where might the real value lie in the market? our own bk dives into one active class you should be buying into. that's next. >>> still ahead on "fast money," the fed fueling a major rally in stocks. one trader said there's more money to be made in another asset class and a buy signal for alib

one area i've owned, big pharma names. the other area, apple. i've owned a lot of these areas for four years to 20 years. i think there are other areas that we're talking about rotation, sure. i think rotation into some of these tech names is a great opportunity. >> so biotech, buy what? >> actually, the tech names are any multinational. i had the few in the correctional phase, it's going to get weaker. are probably a buy here, tech is a big part of it. i think that's not a bad place to be. >> so red flag number one was biotech. red flag number two, oil. hovering around the flatline this morning after jumping higher 2%. crude prices have now climbed 9% in the past week. have we finally seen a bottom in oil? joining us now is dennis garbin. nice to see you. have we seen a bottom? >> it doesn't seem we have possibly seen the bottom. we've seen the front today gain on the back months. you had an outside reversal in crude oil last week. now you're starting to take outside reversals. you're getting a change in the dollar. so i had been manifestly bea

. >>> coming up next, the race for big pharma and cancer drugs.ch stocks might be right for a takeover? >>> later, mark cuban sounding alarm on tech bubble 2.0. we've got the details ahead. >>> earnings alert on the fresh market. morgan brennan has the details. morgan? >> melissa, the fresh market moving higher in after hours trading. earnings that beat consensus analyst estimates. revenue in below expectations. fresh market announcing it will shudder operations in california to focus on other higher growth opportunities. that's sending shares of the stock up about 3% right now in after hours. back over to you. >> thank you, morgan. i would think that california would be a great business -- >> it's a fresh state. it's got the fresh prince of bel-air, too, for that matter. anyway, if you look at the stock, though, what's interesting the reaction in the posterin post earnings is the stock was trapped between $37 and $41. growing margins when the company has been making investments and that's what the street looks like. >> whole foods or hane? >> han

many big pharma companies would die to have the balance sheet a lot of biotechs have.ech is still well intact here sara. >> john spallanzani, make sense of the world for us after all we've been through this week fed speak and all the other things that have been going on here. do we stay the course or did something change for you this week? >> nothing changed for me. as a matter of fact, i think things got better. i think that janet said lower for longer again. everybody is waiting for her to take the punch bowl away. she's not doing that. she's not even prepared to do that right now. >> do you still hold bonds then treasuries? >> i think you can. obviously today the 30 went below 2.50% on the close. the 10s are back below 2%. those are big moves and you had a corresponding stock rally. to have bonds rally and stocks rally, she really hit it out of the park. i think that, you know bernanke even said today, you know, it's a little too soon to be tightening. things are good we have to worry about europe. europe is a big issue, and the fact that we have german bunds at 17

they're potentially pursuing a partnership with the big pharma company.ng a sale of itself. we talked about that and he obviously wouldn't comment whether they're going to sell themselves. he says all options are on the table, including a sale or potential partnership. genfit satisfying this is a success, an overreaction. >> wall street doesn't think so. it was down 44% last time i looked. we showed the plus sign and talked about that with brian. is this an opportunity for them? >> that's what folks are saying. they're saying because genfit's drug didn't look to work quite as well intercept's drug emerges as the leader in the class. they're both going to go into phase three studies this year so genfit's argument is still in the race. what is the best research piece you have read on the sector? has the run-up ended? >> credit suisse has a great note out today actually looking at valuations in biotech saying that they do make sense for some of the bigger companies who have really great pipelines. >> depends what you want to pay for growth stocks. meg terrel

i think there are opportunities in pharma. i think there are opportunities as well.t may happen on the cable side. you could see something with dish and one of the other big providers. so i do think that we've only seen the beginning. you will see more as long as money continues to be at this level and i tend to agree with larry's comment about the fed. i think you may see a period longer where rates won't go up and, therefore, you will provide a platform for this kind of opportunity. >> so, bill that's exactly what we're wondering here. on a day like this with the market selling off some worries about economic data does that help or hinder the kind of deal boom we're discussing? >> well i think eric is right. i think we will see more large, very material deals, and i think you got to ask the question why. larry pointed to one reason which is the availability and cost of money. that's very very helpful for the buyer even though he may be dissuaded at the margin by the high values we've got now. you have to ask the question why is that going on? and i think the answer

is potentially starting a correction, biogen, celgene all getting hit and lerszs known, infinity pharma, should we be worried about this area of the market which has helped push the nasdaq to new highs? >> on friday i think it was, you pointed out, that huge run-up in the ivp, reverse close lower, and it's come to fruition. huge sell-off today, down 4%. i still think biotech's in a nice uptrend. if you look back to may, we've had sell-offs of this magnitude a few times since then. but ivp through 320 might change the course of direction. i'm still a believer in biotech, but the trend has been your friend. i think it continue to be. >> 3320 would be a big deal because 335-ish has been good support. >> and think we have seen on volatile days we've moved through this. if you look at the underlying stocks, top weights biogen, amgen, celgene, this makes up about 40% of the index right there. if you look at some of those stocks, all those are not created equal. amgen looks the most defensive. reasonable value but a stock that's been trapped in this range for the last six months. the question